Ibogaine

Iboga, ibogaine, noribogaine & 18-MC

 

 

Jump to:

 

 

Siegel et al. (1996). Effect of ibogaine on the development of tolerance to the analgesic effect of morphine. Experimental and Clinical Psychopharmacology.

Sweetnam et al. (1995). Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology.

Ali et al. (1996). Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. Brain Research.

Bagal et al. (1996). Modulation of morphine-induced antinociception by ibogaine and noribogaine. Brain Research.

Benwell et al. (1996). Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. British Journal of Pharmacology.

Chen et al. (1996). Ibogaine block of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology.

French, Dillon & Ali (1996). Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons. Life Sciences.

Glick et al. (1996). Ibogaine-like effects of noribogaine in rats. Brain Research.

Glick et al. (1996). 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: Effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Research.

Halpern (1996). The use of hallucinogens in the treatment of addiction. Addiction Research.

Hough, Pearl & Glick (1996). Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sciences.

Layer et al. (1996). Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. European Journal of Pharmacology.

Ley, Jeffcoat & Thomas (1996). Determination of ibogaine in plasma by gas chromatography--chemical ionization mass spectrometry. Journal of Chromatography.

Luxton, Parker & Siegel (1996). Ibogaine fails to interrupt the expression of a previously established one-trail morphine place preference. Progress in Neuro-Psychopharmacology & Biological Psychiatry.

Molinari, Maisonneuve & Glick (1996). Ibogaine neurotoxicity: a re-evaluation. Brain Research.

O’Callaghan et al. (1996). Acute and chronic administration of ibogaine to the rat results in astrogliosis that is not confined to the cerebellar vermis. Annals of the New York Academy of Sciences.

Parker & Siegel (1996). Ibogaine interferes with the establishment of conditioned taste avoidance produced by morphine and lithium. Learning and Motivation.

Pearl, Maisonneuve & Glick (1996). Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats. Neuropharmacology.

Popik (1996). Facilitation of memory retrieval by the "anti-addictive"alkaloid, ibogaine. Life Sciences.

Rabin & Winter (1996). Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors. European Journal of Pharmacology.

Rabin & Winter (1996). Effects of ibogaine and noribogaine on phosphoinositide hydrolysis. Brain Research.

Reid et al. (1996). Neuropharmacological characterization of local ibogaine effects on dopamine release. Journal of Neural Transmission.

Scallet, Ye & Ali (1996). NOS and fos in rat and mouse brain regions. Possible relation to ibogaine-induced Purkinje cell loss. Annals of the New York Academy of Sciences.

Scallet et al. (1996). Ibogaine produces neurodegeneration in rat, but not mouse, cerebellum. Neurohistological biomarkers of Purkinje cell loss. Annals of the New York Academy of Sciences.

Schneider, Nagel & Mah (1996). Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. European Journal of Pharmacology.

Sershen, Hashim & Lajtha (1996). Effect of ibogaine on cocaine-induced efflux of [3H] dopamine and [3H] serotonin from mouse striatum. Pharmacology, Biochemistry, and Behavior.

Sershen, Hashim & Lajtha (1996). The effect of ibogaine on Sigma- and NMDA-receptor-mediated release of [3H]dopamine. Brain Research Bulletin.

Staley et al. (1996). Pharmacological screen for activities of 12-hydroxyibogamine: A primary metabolite of the indole alkaloid ibogaine. Psychopharmacology.

Badio, Padgett & Daly (1997). Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Molecular Pharmacology.

Bhargava, Cao & Zhao (1997). Effects of ibogaine and noribogaine on the antinociceptive action of μ-, δ- and κ-opioid receptor agonists in mice. Brain Research.

Bhargava & Cao (1997). Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice. Brain Research.

Blackburn & Szumlinski (1997). Ibogaine effects on sweet preference and amphetamine induced locomotion: Implications for drug addiction. Behavioural Brain Research.

Cao & Bhargava (1997). Effects of ibogaine on the development of tolerance to antinociceptive action of μ-, δ- and κ-opioid receptor agonists in mice. Brain Research.

Glick, Maisonneuve & Pearl (1997). Evidence for roles of κ-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Research.

Helsley, Rabin & Winter (1997). The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus. Life Sciences.

Helsley, Fiorella & Winter (1997). Effects of ibogaine on performance in the 8-arm radial maze. Pharmacology, Biochemistry and Behavior.

Helsley et al. (1997). Effects of chronic ibogaine treatment on cerebellar Purkinje cells in the rat. Brain Research.

Kombian et al. (1997). Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro. Brain Research Bulletin.

Maisonneuve et al. (1997). Ibogaine and the dopaminergic response to nicotine. Psychopharmacology.

Maisonneuve et al. (1997). Time-dependent interactions between iboga agents and cocaine. European Journal of Pharmacology.

Moroz, Parker & Siegel (1997). Ibogaine interferes with the establishment of amphetamine place preference learning. Experimental and Clinical Psychopharmacology.

O’Hearn & Molliver (1997). The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: A model of indirect, trans-synaptic excitotoxicity. The Journal of Neuroscience.

Pearl et al. (1997). Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism. Pharmacology, Biochemistry and Behavior.

Rezvani et al. (1997). Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacology, Biochemistry, and Behavior.

Sershen, Hashim & Lajtha (1997). Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. Brain Research Bulletin.

Vocci & London (1997). Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging. Annals of the New York Academy of Sciences.

Baumann, Rothman & Ali (1998).  Neurochemical and neuroendocrine effects of ibogaine in rats: comparison to MK-801. Annals of the New York Academy of Sciences.

Bienienda et al. (1998). Alteration of electroencephalogram and monoamine concentrations in rat brain following ibogaine treatment. Annals of the New York Academy of Sciences.

Efange et al. (1998). Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes. Journal of Medicinal Chemistry.

Glick et al. (1998). 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology.

Glick & Maisonneuve (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences.

Helsley et al. (1998). Behavioral and biochemical evidence for a nonessential 5-HT 2A component of the ibogaine-induced discriminative stimulus. Pharmacology, Biochemistry and Behavior.

Helsley et al. (1998). The effects of sigma, PCP and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus. Pharmacology, Biochemistry and Behavior.